The FDA approved Eli Lilly’s oral obesity pill Foundayo (orforglipron), positioning a second daily oral GLP-1 receptor agonist to compete with Novo Nordisk’s recently launched oral Wegovy. The approval sets up a rapid commercialization race focused on dosing convenience, insurance access, and uptake in a market projecting continued expansion. In coverage of the lead-up to launch, reporting emphasized that head-to-head data are not yet available and that the products’ differentiation may hinge on regimen practicality—such as whether the drug must be taken with or without food—alongside payer and channel strategy. Analysts and company statements highlight that the near-term competitive fight will likely be shaped by patient labeling nuances and reimbursement positioning as both drugs roll out.